These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24534191)

  • 1. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
    Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
    J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
    Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
    PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
    Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
    Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
    Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A
    J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
    Hovnanian A
    Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
    Kasparek P; Ileninova Z; Zbodakova O; Kanchev I; Benada O; Chalupsky K; Brattsand M; Beck IM; Sedlacek R
    PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
    Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
    J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
    Kishibe M
    J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A proinflammatory role of KLK6 protease in Netherton syndrome.
    Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
    J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
    Zingkou E; Pampalakis G; Sotiropoulou G
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
    Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
    J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
    Briot A; Deraison C; Lacroix M; Bonnart C; Robin A; Besson C; Dubus P; Hovnanian A
    J Exp Med; 2009 May; 206(5):1135-47. PubMed ID: 19414552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
    Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M
    Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.
    de Veer SJ; Furio L; Swedberg JE; Munro CA; Brattsand M; Clements JA; Hovnanian A; Harris JM
    J Invest Dermatol; 2017 Feb; 137(2):430-439. PubMed ID: 27697464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin.
    Ulbricht D; Tindall CA; Oertwig K; Hanke S; Sträter N; Heiker JT
    Biol Chem; 2018 Sep; 399(9):1079-1084. PubMed ID: 29494334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing.
    Bonnart C; Deraison C; Lacroix M; Uchida Y; Besson C; Robin A; Briot A; Gonthier M; Lamant L; Dubus P; Monsarrat B; Hovnanian A
    J Clin Invest; 2010 Mar; 120(3):871-82. PubMed ID: 20179351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocktails of KLK5 Protease Inhibitors and Anti-TNFα Therapeutics: an Effective Treatment for Netherton Syndrome.
    Zingkou E; Pampalakis G; Sotiropoulou G
    J Clin Immunol; 2022 Apr; 42(3):597-605. PubMed ID: 35040012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
    Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V
    Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
    Furio L; Hovnanian A
    Biol Chem; 2014 Sep; 395(9):945-58. PubMed ID: 25153381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.